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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney
disorder. It is characterized by focal development and progressive enlargement of renal cysts leading to end-stage
renal disease. PKD1 and PKD2 have been implicated in ADPKD pathogenesis but genetic features and the size of
PKD1 make genetic diagnosis tedious.
Methods: We aim to prove that high resolution melt analysis (HRM), a recent technique in molecular biology, can
facilitate molecular diagnosis of ADPKD. We screened for mutations in PKD1 and PKD2 with HRM in 37 unrelated
patients with ADPKD.
Results: We identified 440 sequence variants in the 37 patients. One hundred and thirty eight were different. We
found 28 pathogenic mutations (25 in PKD1 and 3 in PKD2 ) within 28 different patients, which is a diagnosis rate
of 75% consistent with literature mean direct sequencing diagnosis rate. We describe 52 new sequence variants in
PKD1 and two in PKD2.
Conclusion: HRM analysis is a sensitive and specific method for molecular diagnosis of ADPKD. HRM analysis is
also costless and time sparing. Thus, this method is efficient and might be used for mutation pre-screening in
ADPKD genes.
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is a hereditary kidney disorder affecting approximately one
in 500 to one in 1000 human live births [1]. It is character-
ized by focal development and progressive enlargement of
renal cysts, leading to end-stage renal disease (ESRD) [2].
ADPKD is genetically heterogeneous and involves two
genes, PKD1 (MIM 601313, chromosome region 16p13.3)
[3] and PKD2 (MIM 173910, 4q21-22) [4]. Mutations in
PKD1 account for approximately 85% of ADPKD cases
and are associated with a more severe disease than PKD2 .
The median age at onset of ESRD is 54.3 [52.7-55.9] years
for individuals with mutation in PKD1 compared to 74.0
[67.2-80.8] years in PKD2 [5]. It has been hypothesized
that a third gene could be implicated in ADPKD [6] but
there is no evidence for this.
Genetic analysis of ADPKD is difficult owing to the
existence of at least two distinct genes that can cause
disease and the lack of an exhaustive list of PKD1 and
PKD2 mutations that are associated with it. Genomic fea-
tures of PKD1 also cause difficulty in identifying
sequence variants [7]. The open reading frame of PKD1
is approximately 13 kb split in 46 exons. Exons 1-33 are
duplicated six times at the HG locus on a proximal posi-
tion on chromosome 16p. The homology between the 5’
region of PKD1 and these six pseudo genes ranges from
94.5 to 96.7% in the duplicated area and almost 100% for
the coding sequence [8]. Locus-specific amplifications of
PKD1 are required for analysis which complicates genetic
diagnosis [9]. Furthermore, PKD1 is a highly polymorphic
gene with numerous sequence variants [10,11] (Human
Gene Mutation Database [HGMD]; http://www.hgmd.cf.
ac.uk/ac/index.php[12]). Single nucleotide variants in the
coding regions of the PKD genes could result in the
development of ADPKD. Therefore, a strategy has been
proposed to investigate the pathogenic significance of
sequence variants in PKD1 [11].
Definitive diagnosis of ADPKD is based on an age-spe-
cific cystic renal phenotype and a positive family history
[13]. Diagnosis of ADPKD in younger patients can be
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difficult as renal ultrasonography can be inconclusive and
if the family history is unknown. Molecular diagnosis
could be of use in providing a definitive diagnosis.
High Resolution Melt (HRM) analysis, a recent
advance in molecular biology used to detect variants in
DNA sequences [14], has replaced dHPLC, the reference
screening method, for analyzing genetic variants of
BRCA1 and BRCA2 [15]. There are major drawbacks
with dHPLC including chemical waste, high mainte-
nance costs and the need for post-PCR manipulations.
Moreover, dHPLC does not allow high-throughput
sequence variation screening.
HRM is based on the analysis of the melting curve of a
real-time PCR amplicon. Monitoring the melting curve of
the amplicon involves detecting the change in fluorescence
intensity induced by the release of an intercalating DNA
dye from a DNA duplex as it denatures at high tempera-
tures. Unlike dHPLC, this technique allows high through-
put screening. Even if the sequence is the endpoint of
molecular analysis, a pre-screening step always reduces
the cost compared to the whole gene sequencing [16].
Therefore, with regard to PKD1 and PKD2 , HRM could
be a rapid and cost effective technology for routine genetic
analysis.
We show the results of an HRM screening strategy to
identify sequence variants within PKD1 and PKD2 in 37
ADPKD patients and demonstrate that HRM is accurate
to study ADPKD genes.
Methods
DNA samples
Thirty-seven unrelated patients from the Nephrology cen-
ter of Marseille were screened for sequence variants in
PKD1 and PKD2 . They all fulfilled the ADPKD unified
diagnosis criteria [17]. The cohort is composed of 14
females and 23 males. The mean age is 51 years+/-11.
They had normal renal function (2 patients) or chronic
renal failure (6 patients) or end-stage renal disease (29
patients). Fifty healthy individuals are the control group.
They are from the same area and ethnic group as patients.
Genomic DNA was extracted from lymphocytes harvested
by venous blood puncture after written informed consent.
Quantification and quality of all experimental DNA sam-
ples were assessed using Nanodrop® Technology (Cole-
man Technologies, Orlando, FL). DNA working solutions
were diluted in ultrapure water to obtain the correct dilu-
tion. The study was conducted in compliance with the
Helsinki Declaration and was approved by the Comité de
Protection des Personnes (CPP) Sud-Méditerranée 2.
Long Range PCR
PKD1 screening previously required amplification of five
specific long range (LR) PCR with primers designed in
the PKD1 sequence differing from the homologues; this
step ensures to screen for sequence variants in PKD1 ,
not in homologues. Long range PCR assays were per-
formed as described previously [18], LR1 amplified exon
1, LR2 amplified exon 2 to 12, LR3 amplified exon 13 to
15D, LR4 amplified exon 15E to 22, LR5 amplified exon
22 to 32. A sixth 7,838 bp LR PCR was designed to make
HRM analysis for PKD1 exons 36 to 46 more specific
with the forward and reverse primers: 5’-ACCTTCCCTC
TAGGGAGGGAGCA-3’ and 3’-GGCCAAGCTCG-
CATCCAAGCA-5’. Amplification was performed using
the GeneAmp High Fidelity PCR System (Applied Biosys-
tems, Foster City, CA) in a final volume of 50 µl contain-
ing 100 ng gDNA, 2.5U enzyme, 15 µM of each primer,
5 mM dNTP, 5 µl manufacturer’s supplied buffer, 2 µl
supplied MgCl2 and 10% DMSO. Cycling conditions
were 95°C for 3 min, followed by 34 cycles at 96°C for
30 s, 62°C for 30 s, 68°C for 8 min, and a last step of
7 min at 72°C. All LR PCR products were verified on
ethidium bromide stained gels.
Primers
We used oligonucleotide primers described in the litera-
ture to perform PCR on each PKD1 and PKD2 exons and
on exon-intron junctions, which is important in order to
identify variants affecting mRNA splicing. Primers from
Tan et al. [18] and from Rossetti et al. [10] were used for
PKD1 analysis; primers from Tan et al. [18] and from
Hayashi et al. [19] were used for PKD2 . Forty-three out
of 46 exons of PKD1 were screened in 56 amplicons; 14
out of 15 exons of PKD2 were screened in 14 amplicons.
Exons 1, 42, 43 of PKD1 and exon 1 of PKD2 could not
be screened by HRM and were sequenced. Details of all
primers are available in additional file 1.
Real Time PCR and HRM conditions
Amplification and HRM were performed in 20 µl
volumes in a LightCycler 480 (Roche Applied Systems).
The amplification mixture included 20 ng of genomic
DNA or 5 µl of 1/500 diluted PCR long range amplifica-
tion product as template, 1 µl of LightCycler 480 Reso-
Light Dye (Roche, Indianapolis, IN), 10 µL of LightCycler
480 Probes Master (Roche, Indianapolis, IN) and 5 µM of
each primer.
Each run included an activation step at 95°C for 10 min
followed by 45 amplification cycles of 15 s denaturation,
15 s annealing and 15 s, elongation at 72°C. Denaturation
and annealing temperatures differed according to each
fragment these are detailed in additional file 1.
First, the products were heated to 96°C for 1 min and
temperature sample was reduced at 40°C for 1 min. HRM
was carried out with the temperature rising at a rate of
1°C per second with 25 acquisitions per degree. Initial and
final temperatures also differed among amplicons (addi-
tional file 1). All reactions were performed in 96-well
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microtiter plates. Each fragment was tested in 10 patients
per run.
HRM analysis
For HRM analysis, the melting curves were normalized
and the temperature shifted (temp-shifted) so that samples
were comparable. Modified curves were obtained with
LC480 software in the gene-scanning module (version 1.3;
Roche). The normalized and temp-shifted melting curves
corresponded to the final curve after normalization. When
an amplicon harbored a sequence variation, the normal-
ized and temp-shifted melting curve had a different shape
from wild-type amplicons.
In this study, normalization was manually adjusted; in a
routine framework, normalization ranges are automatically
filled out. Default software sensitivity setting was 30% in
order to avoid false negative amplicons. Therefore, sensi-
tivity was set by default to 40% for all amplicons.
Comparing several wild-type amplicons demonstrated
that the derived normalized and temp-shifted difference
plot varies within a range owing to small random differ-
ences. The variance is partly caused by the specificity of
the primers. Every amplicon that had a different derived
normalized temp-shifted curve from wild-type was
sequenced.
Reverse transcription analysis
To confirm the signification of the suspected splice muta-
tion c.7210-5C>G, we performed RT-PCR from RNA
extracted of leucocytes as previously described [20], briefly
lymphocytes were isolated using a Ficoll gradient and total
RNA was extracted using the Rneasy Qiagen kit, according
to the manufacturer’s instructions (Qiagen SA). Total
RNA was resuspended in Rnase free water. A total of 5 μg
of total RNA was reverse transcribed using a RT-PCR kit
(RT Life Technology GIBCO BRL), according to the man-
ufacturer’s instructions, and 3 μl of the RT products were
amplified using a standard hot start PCR technique using
the primers, for PKD1 specific PCR (6F 5’-AGCGCAAC-
TACTTGGAGGCCC-3’ and 6R 5’-ACCACAACGGAG
TTGGCGG-3’) and we diluted this RT-PCR product to




Sequencing was used to confirm and investigate variants.
All sequencing analysis was subcontracted to Cogenics®
(Cogenics, Meylan, France) and performed by Sanger
sequencing method. Capillary sequencing is performed
using Big Dye* Terminator chemistry and sequences are
delineated with Applied Biosystems 3730 × l platforms
(http://www.beckmangenomics.com/documents/services/
GS_Sanger_Sequencing.pdf). Samples were prepared by
diluting 20 µl PCR product in 30 µl of ultrapure water.
Primers were diluted to obtain a concentration of 2 mM
as recommended by the subcontractor.
Sequence variation analysis and classification
All sequences were compared to the following refer-
ences sequences NCBI RefSeq PKD1 : NM_000296.2;
and PKD2 : NM_000297.2. The standard nomenclature
recommended by HGVS (http://www.hgvs.org/mutno-
men) was used to number nucleotides and name
mutations.
For previously described sequence variants, we
reported the clinical significance assessed in The Polycys-
tic Kidney Disease Mutation Database accessible at
http://pkdb.mayo.edu[12]. Pathogenic potential of novel
mutations was assessed as follows: - nonsense or frame-
shift variants leading to a STOP codon as well as intronic
mutations altering mRNA sequence proved with RT-PCR
were considered as definitely pathogenic mutations. -
intronic and synonymous variants that did not alter pre-
dicted splicing (http://www.fruitfly.org/seq_tools/splice.
html) were considered as polymorphisms, the others as
indeterminate mutations. - substitutions were evaluated
using the scoring method described by Rossetti et al [11]
and with PolyPhen, a software for interspecies sequence
variations examination (http://genetics.bwh.harvard.edu/
pph) [21]. When the two scores assessed a pathogenic
variant the mutation was considered as probably patho-
genic, when they assessed a non pathogenic variant it was
considered as polymorphism. If the two tests were discor-
dant, the variation was reported as indeterminate.
Results
Forty-three exons of PKD1 were analyzed using HRM in
56 fragments after PCR amplification. Of the 2,072 ampli-
cons tested in the 37 patients, 302 (14.6%) were suspected
to have a sequence variants compared to the wild-type
amplicons analyzed (Figure 1). Each of the 302 amplicons
was sequenced and 244 had at least one sequence variants.
A total of 410 sequence variants were detected in PKD1 ,
corresponding to 11.1 ± 7.7 (mean ± SD) per patient; 3
exons were studied by direct sequencing. 129 different
sequence variants were found.
Fourteen exons of PKD2 were analyzed in 14 frag-
ments after PCR amplification. Of the 518 amplicons
tested, HRM analysis identified 8 with sequence variants
and 4 were shown to have at least one sequence variant
after sequencing. A total of 30 sequence variants were
detected in PKD2, one exon was studied by direct
sequencing. 9 different sequence variants were found.
Table 1 and Figure 2 show definitely pathogenic and
probably pathogenic mutations. 25 mutations in PKD1
and 3 in PKD2 were identified in 28 patients. Of these 28
mutations, 9 were already described in literature. Of the
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19 new mutations, 13 were identified as being definitely
pathogenic because they lead to a STOP codon; 3 substi-
tutions were scored as probably pathogenic (Additional
file 2) as well as 1 in frame deletions, one intronic dele-
tion and one intronic substitution.
The first in frame deletion, p.Thr2337_Phe2338del,
was classified as probably pathogenic because the two
residues are highly conserved during evolution, they are
located in the functional REJ domain and this deletion
was the only probably pathogenic mutation identified in
this patient (Figure 3). The second deletion was p.
Leu2433del. Since leucine 2433 is a conserved residue
(in chicken, frog and takifugu but not in mouse or rat),
this variant was also considered probably pathogenic. It
was the only possible mutation causing disease identified
in this patient. In addition, this mutation was previously
described associated with lack of expression of PC-1 in
primary cilia [22]. The two in frame deletions were not
found in 100 control chromosomes tested.
The 19 base pair intronic deletion in intron 31 (c.10167
+24del19) was considered as probably pathogenic. Unfor-
tunately, this patient was lost of follow up and no RT-
PCR could be performed. A very similar deletion has pre-
viously been reported [23] as probably pathogenic in The
Polycystic Kidney Disease Mutation Database. The dele-
tion is present in three of the HG genes-PKD1 partial
homologues on chromosome 16 (Figure 4) leading to a
splice mutation associated with intron 31 retention. It
was the only possible pathogenic mutation found in this
patient and was not present in the 100 control chromo-
somes tested. The abnormal predicted splicing of intron
31 leads to a frameshift within exon 32. The presence of
this deletion in three of the six PKD1 homologues is of
interest as it is associated with retention of the intron. A
possible hypothesis for the pathogenesis of this mutation
is the occurrence of recombination between homologue
and PKD1. If a crossover event has occurred, it must be a
small crossover, because the deletion region is flanked by
two bases differing from the homologues and identical to
PKD1 (Figure 4). The mutation c.7210-5C>G was pre-
dicted to alter splicing in silico and no other indetermi-
nate or pathogenic variation was found in this patient.
We classified this mutation as pathogenic after we per-
formed a specific RT-PCR as previously described [20].
Figure 1 Example of HRM analysis result: normalized and temp-shifted result curve of fragment 15D of 10 patients. The three
fragments with the red curves carry the same sequence variant p.Ala1555Ala (c.4665A>C), which is different from the fragment with the green
curve p.Thr1558Thr (c.4674G>A). Fragments with the blue curve have no mutation.
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The mutation is responsive of the retention of intron 18
leading to a frameshift with a stop codon in position
2514.
Polymorphisms are presented in Table 2. We identi-
fied 92 polymorphisms in PKD1 and 6 in PKD2 . Two
intronic variants in PKD1 were predicted to alter spli-
cing but were considered as polymorphisms, c.2985
+4G>A was present in 4 patients, a definite pathogenic
mutation was identified in three and c.2985+5G>A was
present in three individuals who already had a patho-
genic mutation. The p.Glu107Asp novel substitution in
PKD2 was classified polymorphism because it was found
in 15 patients of the cohort, which is not consistent
with a pathogenic mutation.
We found 12 indeterminate sequence variants in PKD1
and none in PKD2 . They are presented in Table 3. The
majority of these variants were substitutions; their scor-
ing is presented in Additional file 2. The small in frame
insertion p.Asp3781_Val3782insGlu was considered as
indeterminate because the patient had another indeter-
minate variant (p.Arg4276Trp) and we could not be sure
of its pathogenicity. The three other indeterminate
sequence variants (p.Ala2704Val, p.Ser2935Phe p.
His3559Pro) are the sole mutation with potential patho-
genicity observed in the three individuals screened.
Discussion
We describe the first sequence variants pre-screening
method for PKD1 and PKD2 using HRM analysis. This
is the first use of this technique in genetic nephrology.
This method has a good diagnosis rate as evidenced by
the identification of a mutation in 75% of our cohort
(including definitely pathogenic and probably pathogenic
mutations), which is the mean diagnosis rate reported
with direct sequencing of the two genes [24]. In com-
parison, Rossetti et al found a diagnosis rate of 62.9%
with direct sequencing [11] and 67% with dHPLC [10].
In addition a recent report of Hoefele et al found a
Table 1 Mutations
DNA change Protein change Intron or exon Fragment Mutation type Clinical significance Reference
PKD1
c.862C>T p.Gln288X Exon 5 5B NONSENSE Definitely pathogenic Novel
c.926_939del14 p.Asp309fs Exon 5 5B FRAMESHIFT Definitely pathogenic Novel
c.2073G>A p.Ala692Thr Exon 10 10 SUBSTITUTION Probably pathogenic Novel
c.3783_3784insC p.Glu1261fs Exon 15 15B FRAMESHIFT Definitely pathogenic Novel
c.5078C>A p.Tyr1693X Exon 15 15E NONSENSE Definitely pathogenic Novel
c.5610C>G p.Asn1870Lys Exon 15 15F SUBSTITUTION Probably pathogenic Novel
c.5923C>T p.Gln1975X Exon 15 15G NONSENSE Definitely pathogenic Novel
c.7008_7013delCCTTCA p.Thr2337_Phe2338del Exon 16 16 DELETION Probably pathogenic Novel
c.7108T>A p.Cys2370Ser Exon 17 17 SUBSTITUTION Probably pathogenic [11]
c.7155_7156insT p.Tyr2386fs Exon 17 17 FRAMESHIFT Definitely pathogenic Novel
c.7298_7300delTGC p.del2433Leu Exon 18 18 DELETION Probably pathogenic [22]
c.7210-5C>G pThr2496fs Intron 18 19 SPLICE Definitely pathogenic Novel
c.8124_8127delGCCC p.Thr2710fs Exon 22 22 FRAMESHIFT Definitely pathogenic Novel
c.9147_9148insG p.Ala3050fs Exon 25 25 FRAMESHIFT Definitely pathogenic Novel
c.9403C>T p.Thr3135Met Exon 27 27 SUBSTITUTION Probably pathogenic Novel
c.9203_9205delGTG p.del3138Val Exon 27 27 DELETION Probably pathogenic [23]
c.9859_9861delCTC p.del3287Leu Exon 29 29 DELETION Probably pathogenic [34]
c.10086C>T p.Gln3363X Exon 31 31 NONSENSE Definitely pathogenic Novel
c.10167+24del19 p.Gln3389fs Intron 31 31 SPLICE Probably pathogenic Novel
c.10932delC p.Arg3646fs Exon 37 37 FRAMESHIFT Definitely pathogenic Novel
c.10945_10952del8 p.3649fs Exon 37 37 FRAMESHIFT Definitely pathogenic Novel
c.11249G>A p.Arg3750Gln Exon 39 39 SUBSTITUTION Probably pathogenic [32]
c.11512C>T p.Gln3838X Exon 41 41 NONSENSE Definitely pathogenic [35]
c.11972delC p.Ala3991fs Exon 43 43 FRAMESHIFT Definitely pathogenic Novel
c.12235+2T>C p.Leu4046fs Exon 44 44 SPLICE Definitely pathogenic [20]
PKD2
c.640G>T p.Glu214X Exon 2 2 NONSENSE Definitely pathogenic Novel
c.974G>A p.Arg325Gln Exon 4 4 SUBSTITUTION Probably pathogenic [11]
c.2533C>T p.Arg845X Exon 14 14 NONSENSE Definitely pathogenic [36]
No mutation was detected in more than one individual.
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mutation detection efficiency of 64,5% by direct sequen-
cing [25].
More than 81% of amplicons suspected to have a
sequence variant after HRM analysis carried one after
sequencing, confirming the specificity of this technology.
Overall, less than 15% of the fragments of PKD1 and
1.5% of the PKD2 fragments analyzed by HRM were
sequenced. Moreover, we screened in a blind procedure
four patients with previously known mutations [20] and
identified all of them. Thus, HRM is efficient, sensitive
and specific for mutation screening in ADPKD genes.
HRM analysis reduced drastically the need for systema-
tic sequencing and the time of sequence analysis.
We describe 52 new sequence variants in PKD1 : 18
were classified as mutation, no mutation was detected in
more than one individual, 23 as polymorphism and 11
as indeterminate variant. We report one new mutation
and one polymorphism in PKD2 .
Large deletions or duplications represent 4% of
ADPKD pathogenic variants [26]. HRM technology
allows genomic qPCR screening to be performed for
large deletions/duplications in the same run. Successful
simultaneous analysis by HRM and genomic qPCR has
been described for MLH1 gene [27]. Therefore, it is likely
that HRM and genomic qPCR can be performed simulta-
neously for PKD1 and PKD2 , which will require the
introduction of control DNA and a reference gene in the
microtiter plate. This will improve molecular diagnosis
by directly identifying large deletions/duplications that
have not been identified by HRM analysis or with
sequencing. Therefore, HRM analysis could prove to be a
highly integrated molecular diagnosis tool.
HRM analysis is a high throughput technique for
sequence variants screening PKD1 and PKD2 . The for-
mat of PCR analysis in 96 or 394 well plates allows the
process to be automated after DNA extraction and the
first round of LR PCR for PKD1 . A major advantage of
HRM is a drastic diminution in the needs for sequencing
to identify a sequence variation. HRM could be more
cost effective than direct sequencing for identification of
molecular anomalies in ADPKD. Comparing to dHPLC,
HRM is a closed tube and a non destructive technique.
The PCR and analytical steps are in the same run with
HRM. During dHPLC several separate steps require PCR
products manipulation and can induce mistakes. After
analysis, in HRM the PCR product can be directly
sequenced; in dHPLC the PCR product is destroyed dur-
ing the run and a new PCR must be done for sequencing.
Figure 2 Pathogenic mutations in PKD1 and PKD2 . The pathogenic variants of PKD1 and PKD2 are positioned in a representation of genes
and proteins.
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In our facility, the price for one amplicon analysis with
HRM is 1.52 $ (1.10 €) compared to 4.64 $ (3.36 €) with
dHPLC [28]. In addition, HRM allows large fragment
rearrangements detection in the same step. This techni-
que is very competitive compared to dHPLC. HRM is
time sparing, provides greater security (closed tube dur-
ing the whole process) and is cheaper. Assuming bidirec-
tional sequencing costs 13.8 $ (10 €) per fragment, the
cost for mutation screening in PKD1 and PKD2 with
direct sequencing costs 966 $ (700 €) (70 fragments).
With HRM, 70 fragments × 1.52 $ plus sequencing of
positive fragments (i.e. 9 fragments × 13.8 $), the total
cost is of 230.46 $ (167 €). Furthermore, we do not con-
sider here the technician time sparing provided by HRM
in this cost analysis. Thus, acquiring the needed hardware
for HRM analysis is easily paid off. HRM pre-screening is
cost and time efficient facing direct sequencing in
ADPKD genes.
The technique efficiency will soon be further improved
with the search of conditions allowing the screening of
exons 1 of PKD1 and PKD2 and exons 42 and 43 of PKD1
. We were not able to conduct HRM analysis of these
exons because the denaturation curves could not be ana-
lyzed. We suspected this failure is related to the high GC
contents of the DNA sequence of exon 1 of PKD1 and
PKD2 . For exon 42 and 43 of PKD1 , we suspected the
formation of secondary structures not solved by denatura-
tion temperature. HRM is a rather young technology and
we can expect important developments increasing the effi-
ciency of this sensitive and specific method of screening
[28].
Molecular diagnosis of ADPKD is important for
improving the care of patients [29]. Renal transplanta-
tion from a related living donor at risk of ADPKD is a
concern since clinical and ultrasonographic diagnosis
criteria fail to identify donors with ADPKD when they
are aged less than 40 years [30]. Molecular diagnosis
could be of use in this area as well as identifying muta-
tions in ambiguous phenotypes [31], for example when
the family history is unknown. Genetic diagnosis also
results in a more accurate prognosis [32] as the genes
mutated in ADPKD are the prognostic factors linked to
kidney survival [33]. In addition, therapies development
will probably require an accurate diagnosis in young
Figure 3 Pathogenic variant p. Thr2337_Phe2338del. A. Electrophoregram centered on sequence variant. The black arrow indicates the first
deleted base. B. Alignments between wild type (WT) and mutated DNA sequences (top) and wild-type and mutated protein sequence (bottom).
C. Alignments between deleted region and orthologs. D. Alignments between deleted region and conserved REJ domains.
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Figure 4 Mutation. c.10167+24del19. A. Electrophoregram centered on sequence variant. The black arrow indicates the location of the
deletion. B. Alignments between wild type (WT), mutated and homologues DNA sequences. Black arrows show the flanking bases in the
mutated sequence that is identical to WT but different from the homologues sequence. Black boxes represent a repeated 12 bp regions.
Table 2 Polymorphisms
DNA change Protein change Intron or exon Fragment Mutation type Reference Nb
PKD1
c.107C>A p.Pro36His Exon 1 1 SUBSTITUTION [37] 2
c.114C>T p.Leu38Leu Exon 1 1 SYNONYMOUS Novel 1
c.1023C>T p.Ala341Ala Exon 5 5C SYNONYMOUS [9] 2
c.1119T>C p.Leu373Leu Exon 5 5C SYNONYMOUS [24] 1
c.1323G>A p.Gly441Gly Exon 6 6 SYNONYMOUS [25] 1
c.1607-27C>T Silent Intron 7 8 INTRONIC [10] 3
c.1714C>T p.Pro572Ser Exon 8 8 SUBSTITUTION [10] 1
c.1850-4A>G Silent Intron 9 10 INTRONIC [10] 2
c.2214C>G p.Pro738Pro Exon 11 11A SYNONYMOUS [18] 1
c.2216A>G p.Gln739Arg Exon 11 11A SUBSTITUTION [31] 5
c.2234C>G p.Ala745Ala Exon 11 11A SYNONYMOUS Novel 1
c.2700G>A p.Pro900Pro Exon 11 11B SYNONYMOUS [31] 1
c.2730C>T p.Asp910Asp Exon 11 11B SYNONYMOUS [31] 1
c.2854-5C>T Silent Intron 11 12 INTRONIC [10] 1
c.2985+4G>A Silent Intron 12 12 INTRONIC Novel 4
c.2985+5G>A Silent Intron 12 12 INTRONIC Novel 3
c.2986-15C>T Silent Intron 12 13 INTRONIC [38] 4
c.3063T>C p.Gly1021Gly Exon 13 13 SYNONYMOUS [31] 8
c.3111A>G p.Leu1037Leu Exon 13 13 SYNONYMOUS [9] 7
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Table 2 Polymorphisms (Continued)
c.3275T>C p.Met1092Thr Exon 14 14 SUBSTITUTION [10] 5
c.2395+53G>T Silent Intron 14 14 INTRONIC Novel 1
c.3372C>T p.Ala1124Ala Exon 15 15A SYNONYMOUS [9] 8
c.3375C>T p.Ser1125Ser Exon 15 15A SYNONYMOUS [9] 8
c.3502C>T p.Pro1168Ser Exon 15 15A SUBSTITUTION [10] 2
c.4018C>T p.Arg1340Trp Exon 15 15B SUBSTITUTION [10] 1
c.4071G>T p.Leu1357Leu Exon 15 15C SYNONYMOUS [18] 1
c.4195T>C p.Trp1399Arg Exon 15 15C SUBSTITUTION [31] 8
c.4546G>A p.Ala1516Thr Exon 15 15D SUBSTITUTION [18] 1
c.4665A>C p.Ala1555Ala Exon 15 15D SYNONYMOUS [31] 11
c.4674G>A p.Thr1558Thr Exon 15 15D SYNONYMOUS [38] 4
c.5051C>T p.Ser1684Leu Exon 15 15E SUBSTITUTION [10] 1
c.5172C>T p.Ala1724Ala Exon 15 15E SYNONYMOUS [39] 11
c.5763G>A p.Leu1921Leu Exon 15 15G SYNONYMOUS [9] 1
c.6927C>T p.Gly2309Gly Exon 16 16 SYNONYMOUS [39] 2
c.7165T>C p.Leu2389Leu Exon 17 17 SYNONYMOUS [31] 7
c.7209+16G>A Silent Intron 17 17 INTRONIC Novel 13
c.7210C>T p.Arg2404Trp Exon 18 18 SUBSTITUTION CRISP unpublised 1
c.7441C>T p.Leu2481Leu Exon 18 18 SYNONYMOUS [31] 11
c.7642G>C p.Glu2548Gln Exon 19 19 SUBSTITUTION [39] 1
c.7703+24C>A Silent Intron 19 19 INTRONIC [18] 1
c.7708T>C p.Leu2570Leu Exon 20 20 SYNONYMOUS [32] 8
c.7863+47T>G Silent Intron 20 20 INTRONIC [10] 9
c.7913A>G p.His2638Arg Exon 21 21 SUBSTITUTION [38] 8
c.8016+13delG Silent Intron 21 21 INTRONIC Novel 1
c.8016+26T>C Silent Intron 21 21 INTRONIC [30] 8
c.8016+71G>A Silent Intron 21 21 INTRONIC Novel 1
c.8016+77C>T Silent Intron 21 21 INTRONIC Novel 1
c.8020C>T p.Pro2674Ser Exon 22 22 SUBSTITUTION [40] 2
c.8087T>G p.Leu2696Arg Exon 22 22 SUBSTITUTION [41] 12
c.8123C>T p.Thr2708Met Exon 22 22 SUBSTITUTION [40] 1
c.8161+21T>C Silent Intron 22 22 INTRONIC [30] 13
c.8161+23C>T Silent Intron 22 22 INTRONIC Novel 9
c.8161+24C>G Silent Intron 22 22 INTRONIC Novel 11
c.8161+25A>G Silent Intron 22 22 INTRONIC Novel 11
c.8161+29del18 Silent Intron 22 22 INTRONIC Novel 1
c.8161+30C>G Silent Intron 22 22 INTRONIC Novel 12
c.8161+31C>T Silent Intron 22 22 INTRONIC Novel 12
c.8161+38G>A Silent Intron 22 22 INTRONIC [30] 10
c.8161+39T>C Silent Intron 22 22 INTRONIC [10] 1
c.8161+41C>T Silent Intron 22 22 INTRONIC Novel 1
c.8161+42C>G Silent Intron 22 22 INTRONIC Novel 10
c.8161+46ins18 Silent Intron 22 22 INTRONIC Novel 1
c.8644T>A p.Trp2882Arg Exon 23 23B SUBSTITUTION [18] 1
c.8681_8689del9 p.Ala2894_Ser2896del Exon 23 23B DELETION [11] 1
c.8898G>C p.Glu2966Asp Exon 24 24 SUBSTITUTION [42] 1
c.8913T>C p.Ala2971Ala Exon 24 24 SYNONYMOUS [42] 2
c.8948+17A>G Silent Intron 24 24 INTRONIC [18] 1
c.9195G>C p.Val3065Val Exon 25 25 SYNONYMOUS Novel 1
c.9196T>C p.Phe3066Leu Exon 25 25 SUBSTITUTION [43] 1
c.9260C>G p.Thr3087Thr Exon 26 26 SYNONYMOUS Novel 1
c.9270C>T p.Val3090Val Exon 26 26 SYNONYMOUS [39] 2
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adults to initiate treatment before significant renal
changes have occurred. HRM could be used as a quick
and cost effective genetic test for individuals included in
clinical trials.
Conclusions
HRM analysis is an efficient, sensitive, specific and cost
effective strategy to identify mutations in PKD1 and
PKD2 .
Table 2 Polymorphisms (Continued)
c.9330T>C p.Pro3110Pro Exon 26 26 SYNONYMOUS [44] 12
c.9569-13T>C Silent Intron 27 28 INTRONIC [10] 5
c.9712+30T>G Silent Intron 28 28 INTRONIC Novel 2
c.10050+54A>G Silent Exon 30 30 INTRONIC [10] 5
c.10170+14T>C Silent Intron 31 31 INTRONIC [45] 1
c.10225G>C p.Val3409Leu Exon 33 33 SUBSTITUTION [18] 1
c.10368C>T p.Ala3456Ala Exon 33 33 SUBSTITUTION [18] 1
c.10406-4C>T Silent Intron 33 34 INTRONIC Novel 1
c.10535C>T p.Ala3512Val Exon 35 35 SUBSTITUTION [44] 4
c.10768C>T p.Leu3590Leu Exon 36 36 SYNONYMOUS [46] 5
c.11376G>C p.Ser3792Ser Exon 40 40 SYNONYMOUS [40] 1
c.11537+5_+6insGGG Silent Intron 41 41 INTRONIC [39] 1
c.11682C>T p.Ser3894Ser Exon 42 42 SYNONYMOUS [10] 2
c.11916C>T p.Arg3972Arg Exon 43 43 SYNONYMOUS [39] 5
c.12138+22delG Silent Intron 44 44 INTRONIC [47] 1
c.12176C>T p.Ala4059Val Exon 45 45 SUBSTITUTION [48] 3
c.12201T>C p.Pro4067Pro Exon 45 45 SYNONYMOUS Novel 9
c.12276A>G p.Ala4092Ala Exon 45 45 SYNONYMOUS [31] 5
c.12409C>T p.Leu4137Leu Exon 45 45 SYNONYMOUS [49] 1
c.12630T>C p.Pro4210Pro Exon 46 46A SYNONYMOUS [46] 1
c.12765C>T p.Pro4255Pro Exon 46 46B SYNONYMOUS [50] 1
PKD2
c.83G>C p.Arg28Pro Exon 1 1A SUBSTITUTION [51] 1
c.321A>T p.Glu107Asp Exon 1 1B SUBSTITUTION Novel 15
c.420G>A p.Gly140Gly Exon 1 1B SYNONYMOUS [52] 6
c.568G>A p.Ala190Thr Exon 1 1B SUBSTITUTION [25] 3
c.844-22G>A Silent Intron 3 4 INTRONIC [51] 1
c.1445T>G p.Phe482Cys Exon 6 6 SUBSTITUTION [53] 1
Nb: number of patients carrying the sequence variant.
Table 3 Indeterminate variants
DNA change Protein change Intron or exon Fragment Mutation type Reference Nb
PKD1
c.854C>T p.Ala285Val Exon 5 5B SUBSTITUTION Novel 1
c.4439A>G p.Glu1480Gly Exon 15 15C SUBSTITUTION Novel 1
c.5848G>A p.Val1950Met Exon 15 15G SUBSTITUTION Novel 1
c.8110C>T p.Ala2704Val Exon 22 22 SUBSTITUTION Novel 1
c.8803C>T p.Ser2935Phe Exon 24 24 SUBSTITUTION Novel 1
c.9730G>A p.Arg3244His Exon 29 29 SUBSTITUTION Novel 1
c.10043G>A p.Arg3348Gln Exon 30 30 SUBSTITUTION Novel 1
c.10876A>C p.His3559Pro Exon 36 36 SUBSTITUTION Novel 2
c.11108G>C p.Ser3703Thr Exon 38 38 SUBSTITUTION Novel 4
c.11344_11345insAAG p.Asp3781_Val 3782insGlu Exon 40 40 INSERTION Novel 1
c.11698C>T p.Leu3897Phe Exon 42 42 SUBSTITUTION Novel 1
c.12826C>T p.Arg4276Trp Exon 46 46B SUBSTITUTION [54] 1
Nb: number of patients carrying the sequence variant.
Bataille et al. BMC Nephrology 2011, 12:57
http://www.biomedcentral.com/1471-2369/12/57
Page 10 of 12
Additional material
Additional file 1: Primers used for PKD1 and PKD2 analysis. The file
contains the sequence and characteristic of the primers used for
amplification of PKD1 and PKD2 .
Additional file 2: Scoring details of novel coding sequence
variations. The file contains the score to evaluate the pathogenicity of
the new sequence variations described in the text.
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